-
CBC Group-backed Hasten Biopharma successfully completes acquisition of five cardiovascular and metabolism drugs from Takeda'
31 Mar 2022 08:09 GMT
… of Ebrantil®, Edarbi®, Basen®, Blopress® and Actos®. Employees dedicated to … ecosystem to bring life-changing treatments to chronic disease patients.… the healthcare sector, including pharmaceutical and biotech, medical technology and healthcare services. …
-
Hikma Pharmaceuticals Plc: A High-Quality Company Trading At A Reasonable Price
25 Jun 2020 02:26 GMT
… products include Actos, Amoclan, Blopress, Omnicef, Prograf, and Suprax. … product is on the FDA's drug shortage list in the … essential product for the treatment of COVID-19 in … CEO) and Teva Pharmaceutical (CEO of global generic medicines). What is often …
-
CBC-Backed Hasten Biopharmaceutical Acquires 14 Celltrion Legacy Products
02 Jul 2024 03:19 GMT
… the commercial rights to drugs in various chronic diseases … including Edarbi®, Basen®, Actos®, Blopress®, and Nesina®.
Fu Wei, … vision of addressing unmet medical needs across communities … special offers
from American Pharmaceutical Review – all delivered …
-
Japan Pharma Outlook 2016 - ¥950b Drugs will Go Off Patent in Japan in the Next three Years
04 Apr 2016 10:31 GMT
… unmet medical need/orphan disease where US biotech has … regulatory environment for Regenerative Medicine Drug Development and Drug Repurposing will make … coming time.
Successful launch of Blopress AG, Plavix AG in … 353-1-481-1716
Sector: Pharmaceuticals
-
Hasten Announces Acquisition of 14 Celltrion Legacy Products, Accelerating its Business Expansion in the Pan-Asia Area
10 Jul 2024 09:56 GMT
… with commercial rights to treatments in various chronic disease … include Edarbi®, Basen®, Actos®, Blopress® and Nesina®, spanning across 8 … across the healthcare space, including pharmaceutical, biotech, medical technology, and healthcare services.
Founded …
-
CBC-Backed Hasten Biopharmaceutical Announces Acquisition of 14 Celltrion Legacy Products
01 Jul 2024 00:40 GMT
… with the commercial rights to drugs in various chronic diseases areas … , including Edarbi®, Basen®, Actos®, Blopress®, and Nesina®.
Fu Wei, CEO … across the healthcare space, including pharmaceutical, biotech, medical technology, and healthcare services.
We …
-
Hasten Announces Acquisition of 14 Celltrion Legacy Products, Accelerating its Business Expansion in the Pan-Asia Area
28 Jun 2024 12:39 GMT
… with commercial rights to treatments in various chronic disease … include Edarbi®, Basen®, Actos®, Blopress® and Nesina®, spanning across 8 … across the healthcare space, including pharmaceutical, biotech, medical technology, and healthcare services. Founded …
-
SE Asia Digest: Jirnexu acquires CompareHero; Hasten Biopharma buys Celltrion products
01 Jul 2024 10:40 GMT
… , with the commercial rights to drugs in various chronic diseases areas … diabetes, including Edarbi, Basen, Actos, Blopress, and Nesina.
“This successful acquisition …
-
Japan Biosimilars Research Report 2017: Major JP Innovator vs. Early Entrant Mid Size Japanese Companies - TA focus approach - A Win Win Game
22 Aug 2017 21:07 GMT
… generics launch in Japan (Blopress- Aska, Plavix-Nichi Iko … biosimilar, removing high cost medical care benefit system for … reported by major biopharma drugs in Japan- Biosimilars …
Asahi Glass
Aska Pharmaceuticals
Chugai Pharmaceuticals
Daiichi Sankyo
Fuji …
About
© 1995-2024